Atnaujinkite slapukų nuostatas

Biomarkers of Disease: An Evidence-Based Approach [Minkštas viršelis]

Edited by , Edited by , Edited by , Edited by , Edited by , Edited by
  • Formatas: Paperback / softback, 520 pages, aukštis x plotis x storis: 230x156x26 mm, weight: 820 g, 52 Tables, unspecified; 6 Halftones, unspecified; 56 Line drawings, unspecified
  • Išleidimo metai: 30-Oct-2008
  • Leidėjas: Cambridge University Press
  • ISBN-10: 0521088607
  • ISBN-13: 9780521088602
Kitos knygos pagal šią temą:
Biomarkers of Disease: An Evidence-Based ApproachDidesnis paveikslėlis
  • Formatas: Paperback / softback, 520 pages, aukštis x plotis x storis: 230x156x26 mm, weight: 820 g, 52 Tables, unspecified; 6 Halftones, unspecified; 56 Line drawings, unspecified
  • Išleidimo metai: 30-Oct-2008
  • Leidėjas: Cambridge University Press
  • ISBN-10: 0521088607
  • ISBN-13: 9780521088602
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780521088602.html
This publication takes a critical, evidence-based look at the efficacy of diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction. The use of biomarkers is growing, with a steady stream of products being brought out by the pharmaceutical industry. Some of these assist in diagnosis, others provide a means of monitoring the state of progression of disease and the effectiveness of therapeutic options. However, in many cases the evidence which supports the use of these methods as opposed to traditional biochemical tests has not yet been demonstrated, and it is intended that this volume will help clarify the strengths and weaknesses of using these biomarkers across a wide range of applications and in the various organs of the body. This approach will provide pathologists, clinical biochemists and medical laboratory scientists with an invaluable overview of the diverse applications of biomarkers in medicine.

Recenzijos

Review of the hardback: ' contains an amazing wealth of information I know I will refer to it frequently and will keep it readily accessible on my bookshelf.' Doody's

Daugiau informacijos

A critical, evidence-based look at diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction.
Part I. Assessing and Utilising the Diagnostic and Prognostic Power of
Biomarkers: 1.1. Evidence-based medicine: evaluation of biomarkers;
1.2.Development of biomarkers - the industrial perspective; 1.3. Statistical
approaches to rational biomarker selection; 1.4. Using intelligent systems in
clinical decision support; Part II. Biomarkers of Kidney Disease and
Dysfunction: 2.1. Biomarkers in renal disease; 2.2. The genetics of renal
disease; 2.3. Early markers of nephrotoxicity for environmental and
occupational monitoring; 2.4. The early detection of renal impairment in
diabetes mellitus; Part III. Biomarkers of Bone Disease and Dysfunction: 3.1.
Bone turnover markers in clinical practice; 3.2. Biomarkers of bone
formation; 3.3. Biochemical markers of bone resorption; 3.4. The clinical
application of biomarkers in osteoporosis; 3.5. Sources of pre-analytical
variability in the measurement of biochemical markers of bone turnover; 3.6.
Genetic approaches to the study of complex diseases: osteoporosis; Part IV.
Biomarkers of Liver Disease and Dysfunction: 4.1. Biomarkers of hepatic
disease; 4.2. The immunogenetics of metabolic liver disease; 4.3.
Toxicogenetics of liver dysfunction; 4.4. Prognosis and management of
patients with acute liver failure; 4.5. Biomarkers in artificial and
bioartificial support; 4.6. Prognostic markers in liver disease; 4.7.
Apoptosis: biomarkers and the key role of mitochondria; 4.8. Liver
regeneration: mechanism and markers; 4.9. Determinants of response to viruses
and self in liver disease; 5.0 IL-6-type cytokines and signalling in
inflammation; Part V. Biomarkers of Gastrointestinal Disease and Dysfunction:
5.1. Biomarkers in gastrointestinal disease; 5.2. Tumour markers in
gastrointestinal disease; 5.3. Markers of malabsorption: coeliac disease;
Part VI. Biomarkers in Toxicology: 6.1. Genomics and biomarkers in
toxicology; 6.2. Protein profiling and proteomic databases; 6.3. Biomarkers
for evaluating the safety of genetically modified foods; Part VII. Biomarkers
of Cardiovascular Disease and Dysfunction: 7.1. The impact of biochemical
tests on patient management; 7.2. Cardiac naturetic peptides in risk
assessment of patients with acute myocardial infarction or congestive heart
failure; 7.3. Serum markers of inflammation and cardiovascular risk; 7.4. The
clinical significance of markers of coagulation in acute coronary syndromes;
7.5. Endothelin - what does it tell us about myocardial and endothelial
dysfunction?; 7.6. Homocysteine - a reversible risk factor for coronary heart
disease; 7.7. Matrix metalloproteinases and their tissue inhibitors; Part
VIII.. Biomarkers of Neurological Disease and Dysfunction: 8.1. Biomarkers of
neurodegenerative disorders; 8.2. Traumatic brain injury: assessment by
biochemical serum markers; 8.3. An overview of S-100beta as a clinically
useful biomarker of brain tissue damage; Part IV. Biomarkers in
Transplantation: 9.1. Monitoring heart and lung transplant recipients Marlene
Rose; 9.2. Monitoring liver transplant recipients; 9.3. Chronic allograft
damage index as surrogate marker for chronic allograft rejection; 9.4.
Advances in pharmacodynamic biomarkers for monitoring the response to
immunosuppressive drug therapy; 9.5. The use of biomarkers for monitoing the
response to immunosuppressive drug therapy; 9.6. Post-transplantation bone
disease; 9.7. Molecular diagnosis of cytomegalovirus diseases; 9.8. Diagnosis
and monitoring of inflammatory events in transplant recipients; Index.